Zetomipzomib
- Generic Name
- Zetomipzomib
- Drug Type
- Small Molecule
- Chemical Formula
- C30H42N4O8
- CAS Number
- 1629677-75-3
- Unique Ingredient Identifier
- O4BT6C02M2
- Background
Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).
A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE)
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05781750
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸Southwest Kidney Institute, Surprise, Arizona, United States
🇺🇸Valerius Medical Group and Research Center of Greater Long Beach, Inc., Los Alamitos, California, United States
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
- Conditions
- Autoimmune Hepatitis
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05569759
- Locations
- 🇺🇸
Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04628936
- Locations
- 🇨🇿
KZR Research Site, Prague, Czechia
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
- Conditions
- Immune ThrombocytopeniaAutoimmune Hemolytic Anemia
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Registration Number
- NCT04039477
- Locations
- 🇺🇸
KZR-616 Research Site, Rochester, Minnesota, United States
🇷🇺KZR Research Site, Saint Petersburg, Russian Federation
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04033926
- Locations
- 🇩🇪
KZR Research Site, Göttingen, Germany
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT03393013
- Locations
- 🇺🇸
Hope Clinical Trials, Inc., Miami, Florida, United States
🇦🇺Monash Health, Clayton, Victoria, Australia
🇦🇺The Royal Melbourne Hospital, Parkville, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.